公开(公告)号：US20170087205A1

公开(公告)日：2017-03-30

申请号：US15347870

申请日：2016-11-10

申请人： Palatin Technologies, Inc.

发明人： Carl Spana ,  John H. Dodd ,  Trevor Hallam

IPC分类号： A61K38/10 ,  G01N33/68 ,  A61K9/00

CPC分类号： A61K38/10 ,  A61K9/0019 ,  A61K38/2242 ,  C07K14/582 ,  G01N33/6893 ,  G01N2333/58 ,  G01N2800/32 ,  G01N2800/52

摘要： Use and methods of use of natriuretic peptide mimetics which bind to and activate natriuretic peptide receptor A in patients with a defect, condition, syndrome, disease or mutation resulting in a functional active ANP99-126 deficiency, for treatment or prophylaxis of cardiovascular disease, including but not limited to hypertension, acute coronary syndrome, cardiomyopathy, cardiac remodeling, left-ventricular hypertrophy, congestive heart failure, heart failure, high blood pressure and coronary artery disease, including use of mimetics with a plurality of amino acid residues and at least one amino acid surrogate of formula I: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification.

公开(公告)号：US09352013B2

公开(公告)日：2016-05-31

申请号：US14313258

申请日：2014-06-24

申请人： Palatin Technologies, Inc.

发明人： Carl Spana ,  Robert Jordan ,  Jeffrey D. Edelson

IPC分类号： A61K38/12 ,  C07K7/64 ,  A61P15/00 ,  A61K38/34 ,  A61K31/4178

CPC分类号： A61K38/12 ,  A61K31/4178 ,  A61K38/34

摘要： Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.

摘要翻译： 使用约1.0mg至1.75mg之间的皮肤投与剂量的布鲁米诺苷或其药学上可接受的米曲米知识的盐来治疗女性的女性性功能障碍，同时减少或最小化不希望的副作用。

公开(公告)号：US20220362328A1

公开(公告)日：2022-11-17

申请号：US17864486

申请日：2022-07-14

申请人： Palatin Technologies, Inc.

发明人： Carl Spana ,  Robert Jordan ,  Jeffrey D. Edelson

IPC分类号： A61K38/12 ,  A61K38/34 ,  A61K31/4178

摘要： Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.

公开(公告)号：US20200276275A1

公开(公告)日：2020-09-03

申请号：US16878097

申请日：2020-05-19

申请人： Palatin Technologies, Inc.

发明人： Carl Spana ,  John H. Dodd ,  Marie Makhlina

IPC分类号： A61K38/26 ,  A61K9/00 ,  A61K38/12 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10

摘要： The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.

公开(公告)号：US10660939B2

公开(公告)日：2020-05-26

申请号：US15723755

申请日：2017-10-03

申请人： Palatin Technologies, Inc.

发明人： Carl Spana ,  John H. Dodd ,  Marie Makhlina

IPC分类号： A61K38/26 ,  A61K38/12 ,  A61K9/00 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10

摘要： The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.

公开(公告)号：US20190216888A1

公开(公告)日：2019-07-18

申请号：US16368417

申请日：2019-03-28

申请人： Palatin Technologies, Inc.

发明人： Carl Spana ,  Robert Jordan ,  Jeffrey D. Edelson

IPC分类号： A61K38/12 ,  A61K38/34 ,  A61K31/4178

CPC分类号： A61K38/12 ,  A61K31/4178 ,  A61K38/34

摘要： Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.

公开(公告)号：US10286034B2

公开(公告)日：2019-05-14

申请号：US15642772

申请日：2017-07-06

申请人： Palatin Technologies, Inc.

发明人： Carl Spana ,  Robert Jordan ,  Jeffrey D. Edelson

IPC分类号： A61K38/12 ,  A61K38/34 ,  A61P15/00 ,  A61K31/4178

摘要： Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.

公开(公告)号：US20180085425A1

公开(公告)日：2018-03-29

申请号：US15642772

申请日：2017-07-06

申请人： Palatin Technologies, Inc.

发明人： Carl Spana ,  Robert Jordan ,  Jeffrey D. Edelson

IPC分类号： A61K38/12

CPC分类号： A61K38/12 ,  A61K31/4178 ,  A61K38/34

摘要： Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.

公开(公告)号：US09700592B2

公开(公告)日：2017-07-11

申请号：US14704223

申请日：2015-05-05

申请人： Palatin Technologies, Inc.

发明人： Carl Spana ,  Robert Jordan ,  Jeffrey D. Edelson

IPC分类号： A61K38/12 ,  C07K7/64 ,  A61P15/00

CPC分类号： A61K38/12 ,  A61K31/4178 ,  A61K38/34

摘要： Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.

公开(公告)号：US20140378392A1

公开(公告)日：2014-12-25

申请号：US14313258

申请日：2014-06-24

申请人： Palatin Technologies, Inc.

发明人： Carl Spana ,  Robert Jordan ,  Jeffrey D. Edelson

IPC分类号： A61K38/12

CPC分类号： A61K38/12 ,  A61K31/4178 ,  A61K38/34

摘要： Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.

摘要翻译： 使用约1.0mg至1.75mg之间的皮肤投与剂量的布鲁米诺苷或其药学上可接受的米曲米知识的盐用于治疗女性的女性性功能障碍，同时减少或最小化不良副作用。